Danofloxacin is a fluoroquinolone antibiotic and a type II topoisomerase inhibitor. It has a broad antimicrobial spectrum. It can be used as an anti-infective agent for veterinary use only.
J. A. Schrickx, J. Fink-Gremmels, Danofloxacin-mesylate is a substrate for ATP-dependent efflux transporters, British Journal of Pharmacology, 2009, vol. 150, pp. 463-469
Danofloxacin is a fluoroquinolone antibiotic. In vitro, danofloxacin has activity against 68 field isolates of Mycoplasma species isolated from cattle, swine, and poultry with MICs ranging from 8 to 500 nM. It is protective in vivo against P. multocida, E. coli, and S. choleraesuis in mice with protective doses of 0.31, 0.40, and 2.42 mg/kg, respectively. Formulations containing danofloxacin are widely used to prevent infectious disease in livestock.
Fluorinated quinolone antibacterial.
Danofloxacin is a fluoroquinolone antibacterial for veterinary use, with MIC90 of 0.28 μM
ChEBI: Danofloxacin mesylate is a member of quinolines.
Veterinary Drugs and Treatments
Danofloxacin mesylate injection is indicated for the treatment of
Bovine Respiratory Disease (BRD) associated with Mannheimia
(Pasturella) hemolytica and P. multocida in cattle (not dairy or
veal). Because of the drug’s spectrum of activity, it may also be of
benefit in the treatment of infections caused by Histophilus somni
(Haemophilus somnus) or M. bovis, but the drug is not labeled (at
the time of writing) for treating these pathogens. In other countries,
danofloxacin may be labeled for use in swine and chickens
(non-laying), but in the USA it is illegal to use the drug in an extralabel
manner in food-producing species.
Danofloxacin may be of benefit in treating susceptible infections in
adult horses, camelids and other non-food producing species.
